{"title":"Impact of Changes to In-hospital Drug Formularies on Out-of-hospital Prescription Rates and Cost: A Systematic Review.","authors":"Eduardo Carracedo-Martínez, Nuria Choren-Alvarez, Raquel Vázquez-Mourelle, Adolfo Figueiras","doi":"10.1016/j.clinthera.2024.12.005","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>One of the main goals of an in-hospital drug formulary (in-HDF) is to modulate hospitalized patients' drug utilization. Theoretically, however, in-HDFs could also have an impact on out-of-hospital prescriptions in several ways, including discharged patients taking chronic medications that were initiated during hospitalization, hospital physicians prescribing to outpatients as if in-HDFs were equally applicable to the latter (\"spillover effect\"), and primary care physicians subsequently not changing such prescriptions (\"induced prescription\"). The aim of this study was thus to conduct a systematic review of papers that studied the impact of changes to in-HDF on out-of-hospital prescriptions.</p><p><strong>Methods: </strong>We conducted a search of the PubMed and Embase databases. To be eligible for inclusion, studies had to be reported in English, Spanish, French, or Portuguese; as their designated aim, studies had to seek to evaluate the impact of a change in at least 1 active ingredient in the in-HDF on out-of-hospital prescriptions; and studies had to have at least 1 control period before the in-HDF change or a control group without any such change.</p><p><strong>Findings: </strong>A total of 8 studies met the inclusion criteria: in 7 of these, out-of-hospital drug-utilization rates changed in line with the changes made to in-HDFs, with a decrease if the drug had been removed or restricted and an increase if the drug had been included and/or the opposite for competitor me-too medicines. Only 4 papers analyzed the impact on costs, half of which reported no statistically significant result.</p><p><strong>Implications: </strong>Changes to in-HDFs have an impact on out-of-hospital prescription rates. Further studies are needed to examine the cost aspect since a research gap has been identified.</p>","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clinthera.2024.12.005","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: One of the main goals of an in-hospital drug formulary (in-HDF) is to modulate hospitalized patients' drug utilization. Theoretically, however, in-HDFs could also have an impact on out-of-hospital prescriptions in several ways, including discharged patients taking chronic medications that were initiated during hospitalization, hospital physicians prescribing to outpatients as if in-HDFs were equally applicable to the latter ("spillover effect"), and primary care physicians subsequently not changing such prescriptions ("induced prescription"). The aim of this study was thus to conduct a systematic review of papers that studied the impact of changes to in-HDF on out-of-hospital prescriptions.
Methods: We conducted a search of the PubMed and Embase databases. To be eligible for inclusion, studies had to be reported in English, Spanish, French, or Portuguese; as their designated aim, studies had to seek to evaluate the impact of a change in at least 1 active ingredient in the in-HDF on out-of-hospital prescriptions; and studies had to have at least 1 control period before the in-HDF change or a control group without any such change.
Findings: A total of 8 studies met the inclusion criteria: in 7 of these, out-of-hospital drug-utilization rates changed in line with the changes made to in-HDFs, with a decrease if the drug had been removed or restricted and an increase if the drug had been included and/or the opposite for competitor me-too medicines. Only 4 papers analyzed the impact on costs, half of which reported no statistically significant result.
Implications: Changes to in-HDFs have an impact on out-of-hospital prescription rates. Further studies are needed to examine the cost aspect since a research gap has been identified.
期刊介绍:
Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.